Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial - 29/06/12
, Luis Fayad, MD a, Nicolaus Wagner-Bartak, MD b, Liang Zhang, MD a, Fredrick Hagemeister, ProfMD a, Sattva S Neelapu, MD a, Felipe Samaniego, MD a, Peter McLaughlin, MD a, Michelle Fanale, MD a, Anas Younes, ProfMD a, Fernando Cabanillas, MD f, Nathan Fowler, MD a, Kate J Newberry, PhD a, Luhong Sun, PhD a, Ken H Young, MD c, Richard Champlin, ProfMD d, Larry Kwak, ProfMD a, Lei Feng, MS e, Maria Badillo, BS a, Maria Bejarano, MD a, Kimberly Hartig a, Wendy Chen, PA a, Yiming Chen, MD a, Catriona Byrne, RN g, Neda Bell, BS g, Jerome Zeldis, MD g, Jorge Romaguera, ProfMD aSummary |
Background |
The combination of rituximab and lenalidomide has shown promise for the treatment of mantle-cell lymphoma (MCL) in preclinical studies. We aimed to identify the maximum tolerated dose (MTD) of lenalidomide when combined with rituximab in a phase 1 trial and to assess the efficacy and safety of this combination in a phase 2 trial in patients with relapsed or refractory MCL.
Methods |
Patients with relapsed or refractory MCL who had received one to four previous lines of treatment were enrolled in this single-arm, open-label, phase 1/2 trial at MD Anderson Cancer Center. In phase 1, to identify the MTD of lenalidomide, four patient cohorts received escalating doses (10, 15, 20, and 25 mg) of daily oral lenalidomide on days 1–21 of each 28-day cycle. 375 mg/m2 intravenous rituximab was also administered in four weekly doses during cycle 1 only. In phase 2, patients received rituximab plus the MTD of lenalidomide, following the same cycles as for phase 1. Treatment in both phases continued until disease progression, stem-cell transplantation, or severe toxicity. The primary efficacy endpoint was overall response (complete or partial response). The secondary efficacy endpoint was survival. We used the Kaplan-Meier method to estimate response duration, progression-free survival, and overall survival. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00294632.
Findings |
52 patients were enrolled between Feb 10, 2006 and July 30, 2009, 14 in phase 1 and 44 (including six patients who received the MTD of lenalidomide in the phase 1 portion) in phase 2. The MTD was 20 mg lenalidomide. One patient who was treated with 25 mg lenalidomide developed a grade 4 non-neutropenic infection and died. In the phase 2 portion of the study, grade 3–4 haematological toxicities included neutropenia (29 patients), lymphopenia (16 patients), leucopenia (13 patients), and thrombocytopenia (ten patients). There were only two episodes of febrile neutropenia. Among 44 patients in phase 2, 25 (57%) had an overall response: 16 (36%) had a complete response and nine (20%) had a partial response. The median response duration was 18·9 months (95% CI 17·0 months to not reached [NR]). The median progression-free survival was 11·1 months (95% CI 8·3 to 24·9 months), and the median overall survival was 24·3 months (19·8 months to NR). Five of 14 patients who had received bortezomib treatment before enrolment achieved an overall response.
Interpretation |
Oral lenalidomide plus rituximab is well tolerated and effective for patients with relapsed or refractory MCL.
Funding |
Celgene.
Le texte complet de cet article est disponible en PDF.Plan
Vol 13 - N° 7
P. 716-723 - juillet 2012 Retour au numéro
Article précédent
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
- Wolfgang Wick, Michael Platten, Christoph Meisner, Jörg Felsberg, Ghazaleh Tabatabai, Matthias Simon, Guido Nikkhah, Kirsten Papsdorf, Joachim P Steinbach, Michael Sabel, Stephanie E Combs, Jan Vesper, Christian Braun, Jürgen Meixensberger, Ralf Ketter, Regine Mayer-Steinacker, Guido Reifenberger, Michael Weller, for the NOA-08 Study Group of the Neuro-oncology Working Group (NOA) of the German Cancer Society ‡
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- Diether Lambrechts, Bart Claes, Paul Delmar, Joke Reumers, Massimiliano Mazzone, Betül T Yesilyurt, Roland Devlieger, Chris Verslype, Sabine Tejpar, Hans Wildiers, Sanne de Haas, Peter Carmeliet, Stefan J Scherer, Eric Van Cutsem
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?